Deflamin

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: Deflamin
• 英文别名: [2-[16-(2-chloroethoxy)-12-fluoro-19-formyl-11-hydroxy-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-16,18-dien-8-yl]-2-oxoethyl] acetate
• 化学式: C₂₉H₃₈ClFO₈
• 分子量: 569.1
• InChiKey: QNXUUBBKHBYRFW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  39
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.76
• 拓扑面积：
  108
• 氢给体数：
  1
• 氢受体数：
  9

文献信息

• [EN] OCULAR INSERTS COMPRISING A COVALENTLY LINKED STEROID DIMER<br/>[FR] INSERTS OCULAIRES COMPRENANT UN DIMÈRE STÉROÏDIEN LIÉ DE MANIÈRE COVALENTE
  申请人：INTERFACE BIOLOGICS INC

  公开号：WO2019148291A1

  公开（公告）日：2019-08-08

  The disclosure features ocular inserts for the sustained release of steroids in the treatment ocular conditions. Said ocular inserts are articles formed from a compound of formula D1-L-D2 (A-I), wherein D1 and D2 are steroid radicals selected from the group consisting of an antibiotic steroid, a glucocorticoid steroid, an anti-angiogenic steroid, an intraocular pressure lowering steroid, and a corticosteroid; and L is a linker covalently linking D1 to D2. The article is a fiber, fiber mesh, woven fabric, non- woven fabric, pellet, cylinder, microparticle, nanoparticle, or shaped article. Also disclosed are carbonate and carbonate ester linked dimers of corticosteroids linked at the 3-hydroxyl, the 11-hydroxyl, the 17-hydroxyl, or the 21-hydroxyl positions of the steroid.

  该披露涉及眼用插入物，用于缓释类固醇治疗眼部疾病。所述眼用插入物是由化合物D1-L-D2（A-I）形成的物品，其中D1和D2是类固醇基团，所选自抗生素类固醇、糖皮质激素类固醇、抗血管生成类固醇、降低眼内压力类固醇和皮质类固醇；而L是将D1与D2共价连接的连接剂。该物品是纤维、纤维网、织物、非织造布、颗粒、圆柱体、微粒子、纳米粒子或成型物品。此外，还披露了碳酸盐和碳酸酯连接的皮质类固醇二聚体，连接在类固醇的3-羟基、11-羟基、17-羟基或21-羟基位置。
• Glass formulations and uses thereof
  申请人：Ripple Therapeutics Corporation

  公开号：US10632075B2

  公开（公告）日：2020-04-28

  The disclosure features pharmaceutical compositions formed from prodrug dimers for the extended delivery of a drug and for the treatment of a disease or condition.

  本公开的特征是由原药二聚体形成的药物组合物，用于延长给药时间和治疗疾病或病症。
• GLASS FORMULATIONS AND USES THEREOF
  申请人：Interface Biologics, Inc.

  公开号：US20190275167A1

  公开（公告）日：2019-09-12

  The disclosure features pharmaceutical compositions formed from prodrug dimers for the extended delivery of a drug and for the treatment of a disease or condition.
• OCULAR INSERTS COMPRISING A COVALENTLY LINKED STEROID DIMER
  申请人：Ripple Therapeutics Corporation

  公开号：US20210030667A1

  公开（公告）日：2021-02-04

  The disclosure relates to compounds and compositions for sustained release of ocular therapeutics.